← Back to Search

Serotonin receptor agonist

Eltoprazine HCl 5.0 mg for Parkinson's Disease

Phase 2
Waitlist Available
Research Sponsored by Amarantus BioScience Holdings, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 94 days

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of eltoprazine to treat levodopa-induced dyskinesia in patients with Parkinson's disease

Eligible Conditions
  • Involuntary Movement
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~94 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 94 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical impact of dyskinesia measured by total UDysRS (Unified Dyskinesia Rating Scale) score
Secondary study objectives
Dyskinesia severity using physiological motion sensor system
Patient function using MDS-UPDRS and UDysRS questionnaires quantify dyskinesia and Parkinsonian motor symptoms.
Safety and tolerability: adverse events, physical and neurological exams, safety laboratory values, vital signs and ECG
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Eltoprazine HCl 7.5 mgExperimental Treatment1 Intervention
Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
Group II: Eltoprazine HCl 5.0 mgExperimental Treatment1 Intervention
Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
Group III: Eltoprazine HCl 2.5 mgExperimental Treatment1 Intervention
Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
Group IV: PlaceboPlacebo Group1 Intervention
Placebo capsules to be taken orally b.i.d. for 3 weeks

Find a Location

Who is running the clinical trial?

Amarantus BioScience Holdings, Inc.Lead Sponsor
2 Previous Clinical Trials
41 Total Patients Enrolled
Charlotte Keywood, MBBS,MRCP,Study DirectorAmarantus BioScience Holdings, Inc.
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top